Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced ...

If you have ever wondered whether Novavax is undervalued, overhyped, or a hidden gem in the biotech space, you are definitely not alone. The stock recently ticked up 1.8% over the past week, but has ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...

Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's ...

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

It was 2020 and Maryland biotech Novavax was thinking big. It had a plan to become a COVID vaccine powerhouse, with enough manufacturing capacity to supply the U.S. all by itself, as its executives ...

“The COVID-19 vaccines have had a tremendous positive impact on public health and vaccination continues to be the most effective method for COVID-19 prevention,” Dr. Peter Marks, director of the FDA’s ...

Novavax says its COVID-19 vaccine appears 89% effective, based on early findings from a British study. According to USA Today, the two-dose vaccine was just 60% effective in the South African trial.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...